Third, we found strong evidence in a post hoc analysis that PDE5 inhibitor users were more likely to have had solar keratosis prior to their first PDE5 inhibitor prescription, suggesting that PDE5 inhibitor users were more likely to have experienced excess sun or UV exposure than non-users, even before starting a PDE5 inhibitor. The gene discussed is PDE5A; the disease is actinic keratosis.